Immunohistochemical Markers of Prognosis in Adult Granulosa Cell Tumors of the Ovary - a Review

Overview

Journal J Ovarian Res

Publisher Biomed Central

Specialties Gynecology & Obstetrics
Reproductive Medicine

Date 2023 Mar 3

PMID 36869369

Authors

Dennis Jung

Katrin Almstedt

Marco J Battista

Alexander Seeger

Jorg Jakel

Walburgis Brenner

Annette Hasenburg

Affiliations

Soon will be listed here.

Abstract

Background: Granulosa cell tumors (GCT) are rare malignant ovarian tumors. The two subtypes, adult and juvenile granulosa cell tumors, differ in clinical and molecular characteristics. GCT are low-malignant tumors and are generally associated with favorable prognosis. However, relapses are common even years and decades after diagnosis. Prognostic and predictive factors are difficult to assess in this rare tumor entity. The purpose of this review is to provide a comprehensive overview of the current state of knowledge on prognostic markers of GCT to identify patients with a high risk of recurrence.

Methods: Systematic research for adult ovarian granulosa cell tumors and prognosis revealed n = 409 English full text results from 1965 to 2021. Of these articles, n = 35 were considered for this review after title and abstract screening and topic-specific matching. A specific search for pathologic markers with prognostic relevance for GCT identified n = 19 articles that were added to this review.

Results: FOXL2 mutation and FOXL2 mRNA were inverse and immunohistochemical (IHC) expression of CD56, GATA-4 and SMAD3 was associated with reduced prognosis. IHC analysis of estrogen receptor, Anti-Mullerian hormone (AMH) and inhibin was not associated with prognosis for GCT. Analyses of mitotic rate, Ki-67, p53, β-catenin and HER2 revealed inconsistent results.

Citing Articles

Risk Factors and Clinical Outcomes of Recurrence in Adult Ovarian Granulosa Cell Tumors.

Golmohammadi Tavallaee M, Hasanzadeh Mofrad M, Yousefi Z, Mottaghi M, Homaei Shandiz F, Davachi B Cancer Rep (Hoboken). 2024; 7(10):e70036.

PMID: 39453686 PMC: 11505513. DOI: 10.1002/cnr2.70036.

Pathohistological Findings after Bilateral Ovariectomy in Mares with Behavioral Problems.

Wolf N, Hahn J, Walter I, Zablotski Y, Zerbe H, Witte T Animals (Basel). 2024; 14(19).

PMID: 39409848 PMC: 11475726. DOI: 10.3390/ani14192899.

DNA alterations in ovarian adult granulosa cell tumours: A scoping review protocol.

Karstensen S, Kaiser K, Moos C, Poulsen T, Jochumsen K, Hogdall C PLoS One. 2024; 19(6):e0303989.

PMID: 38875223 PMC: 11178167. DOI: 10.1371/journal.pone.0303989.

References

Sakr S, Abdulfatah E, Thomas S, Al-Wahab Z, Beydoun R, Morris R . Granulosa Cell Tumors: Novel Predictors of Recurrence in Early-stage Patients. Int J Gynecol Pathol. 2017; 36(3):240-252. PMC: 6171102. DOI: 10.1097/PGP.0000000000000325. View

DAngelo E, Mozos A, Nakayama D, Espinosa I, Catasus L, Munoz J . Prognostic significance of FOXL2 mutation and mRNA expression in adult and juvenile granulosa cell tumors of the ovary. Mod Pathol. 2011; 24(10):1360-7. DOI: 10.1038/modpathol.2011.95. View

Mangili G, Ottolina J, Gadducci A, Giorda G, Breda E, Savarese A . Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovary. Br J Cancer. 2013; 109(1):29-34. PMC: 3708585. DOI: 10.1038/bjc.2013.241. View

Heublein S, Mayr D, Vrekoussis T, Friese K, Hofmann S, Jeschke U . The G-protein coupled estrogen receptor (GPER/GPR30) is a gonadotropin receptor dependent positive prognosticator in ovarian carcinoma patients. PLoS One. 2013; 8(8):e71791. PMC: 3739730. DOI: 10.1371/journal.pone.0071791. View

van Meurs H, Schuit E, Horlings H, van der Velden J, van Driel W, Mol B . Development and internal validation of a prognostic model to predict recurrence free survival in patients with adult granulosa cell tumors of the ovary. Gynecol Oncol. 2014; 134(3):498-504. DOI: 10.1016/j.ygyno.2014.06.021. View

Horny H, Marx L, Krober S, Luttges J, Kaiserling E, Dietl J . Granulosa cell tumor of the ovary. Immunohistochemical evidence of low proliferative activity and virtual absence of mutation of the p53 tumor-suppressor gene. Gynecol Obstet Invest. 1999; 47(2):133-8. DOI: 10.1159/000010077. View

Bilandzic M, Chu S, Wang Y, Tan H, Fuller P, Findlay J . Betaglycan alters NFκB-TGFβ2 cross talk to reduce survival of human granulosa tumor cells. Mol Endocrinol. 2013; 27(3):466-79. PMC: 5416929. DOI: 10.1210/me.2012-1239. View

Kyronlahti A, Ramo M, Tamminen M, Unkila-Kallio L, Butzow R, Leminen A . GATA-4 regulates Bcl-2 expression in ovarian granulosa cell tumors. Endocrinology. 2008; 149(11):5635-42. DOI: 10.1210/en.2008-0148. View

Sehouli J, Drescher F, Mustea A, Elling D, Friedmann W, Kuhn W . Granulosa cell tumor of the ovary: 10 years follow-up data of 65 patients. Anticancer Res. 2004; 24(2C):1223-9. View

10.

Wang C, Lv X, Jiang C, Cordes C, Fu L, Lele S . Transforming growth factor alpha (TGFα) regulates granulosa cell tumor (GCT) cell proliferation and migration through activation of multiple pathways. PLoS One. 2012; 7(11):e48299. PMC: 3498304. DOI: 10.1371/journal.pone.0048299. View

11.

Mitri Z, Constantine T, ORegan R . The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. Chemother Res Pract. 2013; 2012:743193. PMC: 3539433. DOI: 10.1155/2012/743193. View

12.

Anttonen M, Pihlajoki M, Andersson N, Georges A, LHote D, Vattulainen S . FOXL2, GATA4, and SMAD3 co-operatively modulate gene expression, cell viability and apoptosis in ovarian granulosa cell tumor cells. PLoS One. 2014; 9(1):e85545. PMC: 3887065. DOI: 10.1371/journal.pone.0085545. View

13.

Volker H, Engert S, Cramer A, Schmidt M, Kammerer U, Muller-Hermelink H . Expression of CD56 isoforms in primary and relapsed adult granulosa cell tumors of the ovary. Diagn Pathol. 2008; 3:29. PMC: 2474830. DOI: 10.1186/1746-1596-3-29. View

14.

Mayr D, Arbogast S, Amann G, Aust D, Diebold J . Characteristic pattern of genetic aberrations in ovarian granulosa cell tumors. Mod Pathol. 2002; 15(9):951-7. DOI: 10.1097/01.MP.0000024290.55261.14. View

15.

Furger C, Fiddes R, Quinn D, Bova R, Daly R, Sutherland R . Granulosa cell tumors express erbB4 and are sensitive to the cytotoxic action of heregulin-beta2/PE40. Cancer Res. 1998; 58(9):1773-8. View

16.

Anttonen M, Parviainen H, Kyronlahti A, Bielinska M, Wilson D, Ritvos O . GATA-4 is a granulosa cell factor employed in inhibin-alpha activation by the TGF-beta pathway. J Mol Endocrinol. 2006; 36(3):557-68. DOI: 10.1677/jme.1.01962. View

17.

Kota S, Gayatri K, Pani J, Meher L, Kota S, Modi K . Ovarian granulosa cell tumor: An uncommon presentation with primary amenorrhea and virilization in a pubertal girl. Indian J Endocrinol Metab. 2012; 16(5):836-9. PMC: 3475918. DOI: 10.4103/2230-8210.100658. View

18.

Roze J, Monroe G, Kutzera J, Groeneweg J, Stelloo E, Paijens S . Whole Genome Analysis of Ovarian Granulosa Cell Tumors Reveals Tumor Heterogeneity and a High-Grade TP53-Specific Subgroup. Cancers (Basel). 2020; 12(5). PMC: 7281495. DOI: 10.3390/cancers12051308. View

19.

Kyronlahti A, Kauppinen M, Lind E, Unkila-Kallio L, Butzow R, Klefstrom J . GATA4 protects granulosa cell tumors from TRAIL-induced apoptosis. Endocr Relat Cancer. 2010; 17(3):709-17. DOI: 10.1677/ERC-10-0041. View

20.

Staibano S, Franco R, Mezza E, Chieffi P, Sinisi A, Pasquali D . Loss of oestrogen receptor beta, high PCNA and p53 expression and aneuploidy as markers of worse prognosis in ovarian granulosa cell tumours. Histopathology. 2003; 43(3):254-62. DOI: 10.1046/j.1365-2559.2003.01706.x. View